Lipoprotein(a) and apolipoprotein(a) isoforms: No association with coronary artery calcification in the Dallas heart study

Circulation

Volumn 111, Issue 12, 2005, Pages 1471-1479

  Guerra, Rudy ^a,b   Yu, Zhaoxia ^a,b   Marcovina, Santica ^c   Peshock, Ronald ^a   Cohen, Jonathan C ^a   Hobbs, Helen H ^a,d,e  

^a Donald W Reynolds Cardiovascular Clinical Research Center   (United States)

^b Rice University   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Apolipoproteins; Arteriosclerosis; Coronary disease; Lipoproteins; Risk factors

Indexed keywords

APOLIPOPROTEIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ETHNIC GROUP; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; POSTMENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE;

ADULT; AFRICAN AMERICANS; APOLIPOPROTEINS A; CALCINOSIS; CORONARY ARTERIOSCLEROSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PARTICLE SIZE; PROTEIN ISOFORMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 16344394833     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000159263.50305.BD     Document Type: Article

References (46)

1. Albers JJ, Adolphson JL, Hazzard WR. Radio-immunoassay of human plasma Lp(a) lipoprotein. J Lipid Res. 1977;18:331-338.
2. Barnathan ES. Has lipoprotein "little" (a) shrunk? JAMA. 1993;270: 2224-2225.
3. Ridker PM. An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. Trends Cardiovasc Med. 1995;5:225-229.
4. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation. 2000;102:1082-1085.
5. Guyton JR, Dahlèn GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985;5:265-272.
6. Heiss G, Schonfeld G, Johnson JL, Heyden S, Hames CG, Tyroler HA. Black-white differences in plasma levels of apolipoproteins: the Evans County Heart Study. Am Heart J. 1984;108:807-814.
7. Keil JE, Sutherland SE, Knapp RG, Lackland DT, Gazes PC, Tyroler HA. Mortality rates and risk factors for coronary disease in Black as compared with White men and women. N Engl J Med. 1993;329:73-78.
8. Otten MW Jr, Teutsch SM, Williamson DF, Marks JS. The effect of known risk factors on the excess mortality of Black adults in the United States. JAMA. 1990;263:845-850.
9. Marcovina SM, Koschinsky ML. Lipoprotein(a) concentration and apolipoprotein(a) size: a synergistic role in advanced atherosclerosis? Circulation. 1999;100:1151-1153.
10. Paultre F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Anerioscler Thromb Vasc Biol. 2000; 20:2619-2624.
11. Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJ, Stampfer MJ, Marcovina SM. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians' Health Study. Clin Chem. 2004; 50:1364-1371.
12. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
13. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;87:2153-2161.
14. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003;278:23260-23269.
15. Kang C, Dominguez M, Loyau S, Miyata T, Durlach V, Angles-Cano E. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol. 2002;22: 1232-1238.
16. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214-1226.
17. Kraft H, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger V, Schonitzer D, Utermann G. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Anerioscler Thromb Vasc Biol. 1996;16:713-719.
18. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999;100:1154-1160.
19. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246: 904-910.
20. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res. 1996;37:2569-2585.
21. Victor RG, Haley RW, Willett D, Peshock RM, Vaeth PC, Leonard D, Basil M, Cooper R, Hobbs HH, for the Dallas Heart Study Investigators. A population-based probability sample for the multidisciplinary study of ethnic disparities in cardiovascular disease: recruitment and validation in the Dallas Heart Study. Am J Cardiol. 2004;93:1473-1480.
22. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, Schwartz RS. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cordial. 1998;31:126-133.
23. Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ, Detrano RC, Dunstan CR, Shah PK, Rajavashisth TB. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA. 2003;100:11201-11206.
24. Bihari-Varga M, Gruber E, Rotheneder M, Zechner R, Kostner GM. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. Arteriosclerosis. 1988;8:851-857.
25. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.
26. Jain T, Yu Z, McGuire D, Peshock R, Willett D, Vega GL, Guerra R, Hobbs HH, Grundy SM, the DHS collaborators. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol. 2004;44:1011-1017.
27. Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol. 1997;79:1298-1301.
28. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: a standardized isoform nomenclature. Clin Chem. 1996;42:436-439.
29. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte MJ, Detrano RC. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-832.
30. Janowitz WR, Agatston AS, Kaplan G, Viamonte MJ. Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women. Am J Cardiol. 1993;72:247-254.
31. Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74: 243-252.
32. Casella G, Berger RL. Statistical Inference. 2nd ed. Pacific Grove, Calif: Duxbury: 2002.
33. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol. 2000;20: 493-499.
34. Jha AK, Varosy PD, Kanaya AM, Hunninghake DB, Hlatky MA, Waters DD, Furberg CD, Shlipak MG. Differences in medical care and disease outcomes among black and white women with heart disease. Circulation. 2003;108:1089-1094.
35. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, Hillis D, Hobbs HH. No association between plasma lipoprotein(a) concentrations and the presence of absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol. 1995;15:850-855.
36. Sorrentino MJ, Vielhauer C, Eisenbart JD, Fless GM, Scanu AM, Feldman T. Plasma lipoprotein(a) protein concentration and coronary artery disease in black patients compared with white patients. Am J Med. 1992;93:658-662.
37. Knapp RG, Schreiner PJ, Sutherland SE, Keil JE, Gilbert GE, Klein RL, Harnes C, Tyroler HA. Serum lipoprotein(a) levels in elderly black and white men in the Charleston heart study. Clin Genet. 1993;44:225-231.
38. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subtractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-1113.
39. Rotimi CN, Cooper RS, Marcovina SM, McGee D, Owoaje E, Ladipo M. Serum distribution of lipoprotein(a) in African Americans and Nigerians: potential evidence for a genotype-environmental effect. Genet Epidemiol. 1997;14:157-168.
40. Ali S, Bunker CH, Aston CE, Ukoli FA, Kamboh MI. Apolipoprotein A kringle 4 polymorphism and serum lipoprotein (a) concentrations in African blacks. Hum Biol. 1998;70:477-490.
41. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol. 2001;37:434-439.
42. Armstrong V, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis. 1986;62:249-257.
43. Maher VM, Brown BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol. 1995;6:229-235.
44. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, Fruchart JC, Ducimetiere P. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis. 2002;163:377-384.
45. Sun H, Unoki H, Wang X, Liang J, Ichikawa T, Arai Y, Shiomi M, Marcovina SM, Watanabe T, Fan J. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem. 2002;277:47486-47492.
46. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol. 1999;10:225-236.